NCT02354443 - A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

February 28, 2017

Conditions

Metabolic Disorders

Interventions

BIOLOGICAL

ProHema-CB Transplant

ProHema-CB, the cellular product, represents the cell populations contained within a human UCB unit after modulation on the day of transplantation by an ex vivo incubation process with the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 (also referred to as FT1050). The cell populations include hematopoietic stem and progenitor cells.

Trial Locations (2)

27705

Duke University Medical Center, Durham

02115-5450

Boston Children's Hospital, Boston